Skip to main content

Dr. Laura Spring, M.D.

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
15
In the NPI registry since
2011
Medicare patients seen, 2024
333

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2011Medical school: University of Massachusetts Medical School
  • 2011Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    MA license 256404

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
333
Services billed
1,027
Patients’ average age
74
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 40-54 minutes24794
Established patient office or other outpatient visit, 30-39 minutes216181

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 6 companies reported 22 payments worth $17,927 in total to this clinician.

By type
Consulting Fee$17,044
Food and Beverage$883

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Apr 23, 2025AstraZeneca Pharmaceuticals LP
Apr 23, 2025
Consulting Fee
DATROWAY · Oncology
$2,740
May 14, 2025Daiichi Sankyo Inc.
May 14, 2025
Consulting Fee
DATROWAY · ONCOLOGY
$2,569
Nov 13, 2025AstraZeneca Pharmaceuticals LP
Nov 13, 2025
Consulting Fee
DATROWAY · Oncology
$2,460
Dec 18, 2025Gilead Sciences, Inc.
Dec 18, 2025
Consulting Fee
Trodelvy · ONC
Company’s description;4283678;VEM US;11099519
$2,180
May 31, 2025Novartis Pharmaceuticals Corporation
May 31, 2025
Consulting Fee
KISQALI · Oncology
$2,100
Feb 11, 2025AstraZeneca Pharmaceuticals LP
Feb 11, 2025
Consulting Fee
LYNPARZA · Oncology
$1,370
Feb 6, 2025AstraZeneca Pharmaceuticals LP
Feb 6, 2025
Consulting Fee
LYNPARZA · Oncology
$1,370
Mar 7, 2025AstraZeneca Pharmaceuticals LP
Mar 7, 2025
Consulting Fee$820
Sep 2, 2025AstraZeneca Pharmaceuticals LP
Sep 2, 2025
Consulting Fee$615
Apr 14, 2025AstraZeneca Pharmaceuticals LP
Apr 14, 2025
Consulting Fee$410
All 11 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 18, 2025Gilead Sciences, Inc.
Dec 18, 2025
Consulting Fee
Trodelvy · ONC
Company’s description;4283678;VEM US;11099519
$2,180
Dec 1, 2025AstraZeneca Pharmaceuticals LP
Dec 1, 2025
Consulting Fee$410
Nov 13, 2025AstraZeneca Pharmaceuticals LP
Nov 13, 2025
Consulting Fee
DATROWAY · Oncology
$2,460
Sep 2, 2025AstraZeneca Pharmaceuticals LP
Sep 2, 2025
Consulting Fee$615
May 31, 2025Novartis Pharmaceuticals Corporation
May 31, 2025
Consulting Fee
KISQALI · Oncology
$2,100
May 14, 2025Daiichi Sankyo Inc.
May 14, 2025
Consulting Fee
DATROWAY · ONCOLOGY
$2,569
Apr 23, 2025AstraZeneca Pharmaceuticals LP
Apr 23, 2025
Consulting Fee
DATROWAY · Oncology
$2,740
Apr 14, 2025AstraZeneca Pharmaceuticals LP
Apr 14, 2025
Consulting Fee$410
Mar 7, 2025AstraZeneca Pharmaceuticals LP
Mar 7, 2025
Consulting Fee$820
Feb 11, 2025AstraZeneca Pharmaceuticals LP
Feb 11, 2025
Consulting Fee
LYNPARZA · Oncology
$1,370
Feb 6, 2025AstraZeneca Pharmaceuticals LP
Feb 6, 2025
Consulting Fee
LYNPARZA · Oncology
$1,370

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Massachusetts →

Industry-funded research

Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $2,849,414 in research payments for these studies, mostly to the institutions running them.

  • A phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized Breast Cancer (NeoSTAR)
    Merck Sharp & Dohme LLC
  • A phase 2 study of response-guided neoadjuvant Sacituzumab govitecan (IMMU-132) in patients with localized Breast Cancer
    Gilead Sciences, Inc.
  • P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, Triple Negative Breast Cancer
    Merck Sharp & Dohme LLC
  • A phase 1B2 openlabel study of disitamab vedotin in combination with other anticancer therapies in solid tumors
    Pfizer Inc.
  • STUDY NAME#HR P-RAD# A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HR Breast Cancer
    Merck Sharp & Dohme LLC
  • A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Posi…
    Merck Sharp & Dohme LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Boston

Sources

NPI registry (CMS NPPES, November 2026; record last updated January 13, 2026), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1811282957. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.